Genetic polymorphism and antioxidant activity in interventions of tobacco-related diseases of the abdominal aorta

Fevzi S. Türker1, Ayşe Doğan2, Yusuf Özşensoy3

1 Department of Cardiovascular Surgery, Elazığ Training and Research Hospital, University of Health Sciences, Elazığ, Turkey
2 Department of Physiotherapy and Rehabilitation, Health High School, Bitlis Eren University, Bitlis, Turkey
3 Department of Veterinary Biometrics and Genetics, Faculty of Veterinary Medicine, Sivas Cumhuriyet University, Sivas, Turkey

Submitted: 24 March 2019; Accepted: 26 April 2019
Online publication: 7 August 2019

Arch Med Sci 2021; 17 (6): 1071–1077
DOI: https://doi.org/10.5114/aoms.2019.86760
Copyright © 2019 Termedia & Banach

Abstract

Introduction: The aim of this study was to determine the genetic polymorphisms of some antioxidant enzymes together with oxidative stress and the response of some antioxidant enzymes against this situation in vascular and endovascular interventions performed for diseases of the infrarenal abdominal aorta.

Material and methods: Twenty-four current or ex-smoker patients (eight aortoiliac occlusive disease (AOD), 16 abdominal aortic aneurysm (AAA)) who were operated were included in this pilot study. Malonyl dialdehyde (MDA) levels, as an indicator of oxidative stress, reduced glutathione, catalase and superoxide dismutase enzymes, which are indicators of antioxidant status, which were measured in aortofemoral bypass in AODs, and in endovascular abdominal aortic aneurysms repairs in the preoperative, operative, and postoperative periods. Genetic polymorphisms of these antioxidant enzymes developing a response to the damage in the preoperative blood samples were determined by using the PCR-RFLP method.

Results: The lack of a significant increase of MDA (nmol/ml preoperative: 2.57 ±0.19, operative: 2.59 ±0.21, postoperative: 2.64 ±0.22, p = 0.63) in the oxidative damage in the operative and postoperative periods compared to the preoperative period prevented the damage and was thought to be associated with the elevation of some effective antioxidant parameters in the operative and postoperative periods.

Conclusions: It may be thought that both types of interventions are quite reliable in terms of oxidative damage and, accordingly, the effect of the procedure-associated oxidative damage in the postoperative complications is low or ineffective. Two genotypes were obtained in each of the three gene areas of the patients, and no statistical significance was determined between the genotypes (p > 0.05).

Key words: aorta occlusive disease, abdominal aortic aneurysms, oxidative stress, gene polymorphism.

Introduction

Aortoiliac occlusive disease triggered by atherosclerosis is a serious cause of mortality and morbidity worldwide. It begins at the terminal aor-
Abdominal aortic aneurysms (AAAs) are permanent localised dilatations in which the diameter of the abdominal aorta is larger than 3 cm. It is a complex and multifactorial disease with a strong genetic component [5]. Xiong et al. revealed that the initial changes in an experimental model of aneurysms were caused by the local production of reactive oxygen species (ROS) [6]. Comparison of endovascular AAA repair (EVAR) with open repair showed EVAR procedures offering excellent early and long-term results [7]. Affecting gene expression via DNA methylation, smoking is the most important environmental factor in the development, progression, and rupture of the disease [8].

Oxidative stress arises from an imbalance between production of ROS and antioxidant capacity of the biological system. Manganese superoxide dismutase (MnSOD), glutathione peroxidase (GPx), and catalase (CAT) enzymes all have critical importance in the antioxidant system [8]. Significance of antioxidant stress is highlighted in the pathogenesis of numerous diseases. Studies have also been conducted to determine the gene polymorphisms of these enzymes [9–13]. However, no genetic study on these antioxidant enzyme gene polymorphisms in the patient group investigated in the present study was found in the literature review.

Smoking is also a cause of oxidative stress. Epigenetic modification of chromosomes is changed by oxidative stress and smoking. Histone acetylation and inflammatory gene promoter methylation increase the over-expression of inflammatory genes in the epithelial cells [14].

The aim of this study was to determine the genetic polymorphisms of these antioxidant enzymes together with oxidative stress and the response of some antioxidant enzymes against this situation in vascular and endovascular interventions performed for smoking related diseases of the infrarenal abdominal aorta. MDA blood levels, as an indicator of oxidative stress, reduced glutathione (GSH), CAT, and SOD, which are indicators of antioxidant status. Blood levels were measured in AFB in AODs, and in EVARs in the preoperative, operative, and postoperative periods. Genetic polymorphisms of these antioxidant enzymes developing a response to the damage in the preoperative blood samples were determined by using the PCR-RFLP method.

Material and methods

Preparation of the patients for the operation and sample collection

All the patients (8 patients) suffering from aortoiliac occlusion and/or stenosis and AAAs (16 patients) were hospitalised at our centre one or 2 days earlier, in order to make their surgical preparations. These two groups were evaluated together because both of these diseases of the abdominal aorta are related with smoking and all patients were smokers or ex-smokers. Also, this was a single-centre pilot study, and so the patient populations were small. Informed written consent was obtained from all patients. Ethics Committee approval was obtained for the study from Fırat University in our city (2015-15).

Once endovascular grafts were prepared in appropriate sizes for 16 patients with AAAs according to their computed tomography (CT) angiography, they were brought to our centre (Medtronic Endurant II). Then, radial artery catheters were inserted to obtain preoperative samples and to allow appropriate monitoring together with the first blood gas analysis. Each of these patients was positioned on the operating table, and spinal anaesthesia was given through drugs containing heavy marcain and fentanyl. Patients were then taken to the angiography laboratory. At the angiography laboratory, the anaesthesia device and all kinds of infusion pumps were prepared. Invasive blood pressure, ECG, and PO2 monitoring were carried out. During the procedure, the patient was sedated with midazolam when required. EVAR was applied from the common femoral arteries by opening both groins. At the end of the procedure, all the patients were taken to their beds in the intensive care unit without mechanical ventilation. In the meantime, operative samples were taken from the radial artery catheter. Almost 24 h after the procedure, postoperative samples were taken in the same way from the patients.

Eight patients having AOD were taken to the operating room on the morning, and after appropriate monitoring they were intubated and general anaesthesia was induced by administering 100 mg lidocaine IV, 300 mg magnesium IV, 100 µg fentanyl IV, 0.6–1.2 mg/kg Esmeron IV, and 2 mg/kg propofol IV. The anaesthesia was maintained performed with isoflurane inhalation anaesthesia, fentanyl and Esmeron. Preoperative samples were taken from the radial artery catheter inserted before anaesthesia. Midline abdominal incision, retroperitoneal approach, and infrarenal cross clamping as well as AFB using Dacron prosthetic grafts were performed. In the postoperative period, the
patients were taken to the intensive care unit with mechanical ventilation. Here, the operative samples were taken from the radial artery catheter. A third set of postoperative samples were taken from the patients about 24 h later. No mortality occurred in either patient group.

**Sample collection**

Once blood samples were taken in two heparin-containing experimental tubes, they were taken to the laboratory. While one of the heparinised bloods was used as the full blood, the other heparinised blood was centrifuged at 3000 rpm for 5 min. Its plasma was separated and washed three times by using physiological saline solution. Then, it was kept in the deep-freezer at −80°C before biochemical analyses. MDA, SOD, GSH, and CAT measurements were done by Mrs. Doğan by manual method in the laboratories of Fırat University, Faculty of Veterinary, Department of Biochemistry. Genetic analysis was done by Mr. Özşensoy in Sivas Cumhuriyet University, Faculty of Veterinary Medicine, Department of Veterinary Biometrics and Genetics.

**Biochemical analyses**

**Lipid peroxidation**

The MDA assay in plasma was conducted with slight modifications according to the method of Placer et al. The resulting MDA created a pink complex with thiobarbituric acid (TBA), and the absorbance was read at 532 nm. The plasma MDA content was expressed as nmol/ml [15].

**Reduce glutathione level**

The educe glutathione (GSH) contents were determined according to the method of Chavan et al. and were expressed as µmol/g Hb [16].

**Catalase activity**

The Aebi method was used for the measurement of CAT activity. The degradation rate of H$_2$O$_2$ by CAT was spectrophotometrically measured based on the fact that H$_2$O$_2$ absorbs light at a wavelength of 240 nm. CAT activity was calculated as katal/g Hb [17].

**Superoxide dismutase activity**

The SOD enzyme activity was measured based on nitro blue tetrazolium (NBT) degradation by superoxide radical, which was produced with the xanthine-xanthine oxidase system. The formozan obtained at the end of the reactions exhibits a blue colour and maximally absorbs at 560 nm [18]. The SOD enzyme activity was calculated as U/g Hb.

**Genetic analysis**

Blood samples of 3 ml were taken in tubes containing K$_2$EDTA and were brought to the laboratory under cold chain as soon as possible. The blood samples were kept at −20°C until the time of analysis. DNA isolation from the blood samples was extracted by using the standard phenol/chloroform method [19].

The DNA samples extracted were amplified to the gene region by using specific primers (Table I). PCR was performed in 15 µl volume including 1 × Mg$^{2+}$ free PCR buffer (Fermentas), 200 mM dNTPs (Fermentas), 1.5 mM MgCl$_2$ (Fermentas), 0.375 U of Tag polymerase (Fermentas), 5 pMol each primer, and ~50 to 100 ng of genomic DNA in each reaction (Table I).

All the PCR products were amplified by using the Touchdown PCR profile [20]. The first step was initial denaturation at 95°C for 4 min, followed by 16 cycles of denaturation at 94°C for 30 s, with annealing beginning at 60°C and ending at 52°C for 30 s and elongation at 72°C for 30 s. The annealing temperature was decreased by 0.5°C per cycle until it reached 52°C. At the second step, 25 cycles of 94°C for 30 s, 52°C for 30 s, and 72°C for 30 s was applied. The final elongation of 72°C for 10 min was applied in all reactions.

The PCR products obtained were digested by using the restriction enzymes specified in Table I. For the digestion process, a total of 30 ml was prepared as 10 ml PCR product, 1 ml restriction enzyme (fastdigest, 10 U/ml), 2 ml enzyme buffer, and 17 ml bidistilled water, and the samples were kept at 37°C for 20 min. The products obtained as

| Locus  | Primer sequence (5’ → 3’) | PZR (bp) | Restriction enzymes | Reference         |
|--------|--------------------------|----------|---------------------|-------------------|
| MnSOD  | F: ACCAGCAGGCAGCTGCGGGG  | 107      | NgoM IV (MroN I)    | Ambrosone et al., 1999 |
|        | R: GCATTGATGAGGTCCCAAG  |          |                     |                   |
| CAT    | F: TAAAGCTGTGAAGAACATAGCT| 185      | Sma I               | Forsberg et al., 2001 |
|        | R: AGAGCTCCGCCCCGCGAGACGG|        |                     |                   |
| GPx3   | F: GAAATCCAGCCGGGCTA    | 253      | Bsa I (Eco3 I)      | Voetsch et al., 2007 |
|        | R: CACTCACCTCGACTTCTTTGC|          |                     |                   |

F – forward, R – reverse.
Results

Physicians performing vascular and endovascular interventions for infrarenal vascular disease have to treat an older and higher risk patient pop-

Table II. Results of the oxidative and antioxidant parameters in patients with diseases of abdominal aorta in preoperative, operative, and postoperative periods

| Parameter | Preoperative period | Operative period | Postoperative period | P-value |
|-----------|---------------------|------------------|----------------------|---------|
| MDA [nmol/ml] | 2.57 ±0.19<sup>a</sup> | 2.59 ±0.21<sup>a</sup> | 2.64 ±0.22<sup>a</sup> | > 0.05 (0.63) |
| GSH [µmol/g Hb] | 1.63 ±0.23<sup>a</sup> | 2.15 ±0.35<sup>a</sup> | 2.24 ±0.31<sup>a</sup> | < 0.05 (0.02) |
| CAT [k/U Hb] | 28.49 ±4.35<sup>a</sup> | 27.37 ±3.38<sup>a</sup> | 30.58 ±3.47<sup>a</sup> | < 0.05 (0.00) |
| SOD [U/g Hb] | 33.06 ±1.92<sup>a</sup> | 32.79 ±1.43<sup>a</sup> | 31.22 ±1.24<sup>a</sup> | < 0.05 (0.01) |

<sup>a</sup>different groups in the same row.
It is important to understand the effect of oxidative damage in determining the possible risks and mortality associated with interventions to improve management during and after the operation.

In the present study, MDA levels, an indicator of oxidative stress, showed a modest increase in operative and postoperative levels, but this increase was not statistically significant. This might be associated primarily with the increase in GSH and CAT levels, which were the parameters of the study, in preoperative and postoperative periods and furthermore such interventions did not result significantly in oxidative stress. When the open surgery and EVAR were compared, it was observed that MDA levels were almost the same in endovascular repair. The open surgery group undergoing AFB (bilateral or unilateral) had a significant decrease only in the postoperative period compared to the endovascular group. When the GSH levels were examined, it was observed that mean values were significantly higher in the AFB group than the endovascular group and there was a difference in

| Parameter                  | Preoperative period | Operative period | Postoperative period |
|----------------------------|--------------------|-----------------|---------------------|
| MDA (EVAR) [nmol/ml]       | 2.24               | 2.32            | 2.23*               |
| MDA (AFB) [nmol/ml]        | 2.07               | 2.2             | 1.88*               |
| P-value                    | > 0.05 (0.13)      | > 0.05 (0.27)   | < 0.05 (0.02)       |
| GSH (EVAR) [µmol/g Hb]     | 0.97*              | 1.72            | 1.02                |
| GSH (AFB) [µmol/g Hb]      | 2.56*              | 2.14            | 2.93                |
| P-value                    | < 0.05 (0.00)      | > 0.05 (0.14)   | > 0.05 (0.19)       |
| CAT (EVAR) [k/g Hb]        | 21.71              | 32.05           | 25.47               |
| CAT (AFB) [k/g Hb]         | 15.66              | 14.88           | 17.94               |
| P-value                    | > 0.05 (0.07)      | > 0.05 (0.06)   | > 0.05 (0.06)       |
| SOD (EVAR) [U/g Hb]        | 31.17*             | 35.53           | 31.15               |
| SOD (AFB) [U/g Hb]         | 29.18*             | 29.09           | 29.63               |
| P-value                    | < 0.05 (0.02)      | > 0.05 (0.07)   | > 0.05 (0.06)       |

*a,b Statistically significant groups.

| Parameter                  | Preoperative period | Operative period | Postoperative period |
|----------------------------|--------------------|-----------------|---------------------|
| MDA (EVAR) [nmol/ml]       | 2.24               | 2.32            | 2.23*               |
| MDA (AFB) [nmol/ml]        | 2.07               | 2.2             | 1.88*               |
| P-value                    | > 0.05 (0.13)      | > 0.05 (0.27)   | < 0.05 (0.02)       |
| GSH (EVAR) [µmol/g Hb]     | 0.97*              | 1.72            | 1.02                |
| GSH (AFB) [µmol/g Hb]      | 2.56*              | 2.14            | 2.93                |
| P-value                    | < 0.05 (0.00)      | > 0.05 (0.14)   | > 0.05 (0.19)       |
| CAT (EVAR) [k/g Hb]        | 21.71              | 32.05           | 25.47               |
| CAT (AFB) [k/g Hb]         | 15.66              | 14.88           | 17.94               |
| P-value                    | > 0.05 (0.07)      | > 0.05 (0.06)   | > 0.05 (0.06)       |
| SOD (EVAR) [U/g Hb]        | 31.17*             | 35.53           | 31.15               |
| SOD (AFB) [U/g Hb]         | 29.18*             | 29.09           | 29.63               |
| P-value                    | < 0.05 (0.02)      | > 0.05 (0.07)   | > 0.05 (0.06)       |

*a,b Statistically significant groups.

| Parameter                  | Preoperative period | Operative period | Postoperative period |
|----------------------------|--------------------|-----------------|---------------------|
| MDA (EVAR) [nmol/ml]       | 2.24               | 2.32            | 2.23*               |
| MDA (AFB) [nmol/ml]        | 2.07               | 2.2             | 1.88*               |
| P-value                    | > 0.05 (0.13)      | > 0.05 (0.27)   | < 0.05 (0.02)       |
| GSH (EVAR) [µmol/g Hb]     | 0.97*              | 1.72            | 1.02                |
| GSH (AFB) [µmol/g Hb]      | 2.56*              | 2.14            | 2.93                |
| P-value                    | < 0.05 (0.00)      | > 0.05 (0.14)   | > 0.05 (0.19)       |
| CAT (EVAR) [k/g Hb]        | 21.71              | 32.05           | 25.47               |
| CAT (AFB) [k/g Hb]         | 15.66              | 14.88           | 17.94               |
| P-value                    | > 0.05 (0.07)      | > 0.05 (0.06)   | > 0.05 (0.06)       |
| SOD (EVAR) [U/g Hb]        | 31.17*             | 35.53           | 31.15               |
| SOD (AFB) [U/g Hb]         | 29.18*             | 29.09           | 29.63               |
| P-value                    | < 0.05 (0.02)      | > 0.05 (0.07)   | > 0.05 (0.06)       |

*a,b Statistically significant groups.

| Parameter                  | Preoperative period | Operative period | Postoperative period |
|----------------------------|--------------------|-----------------|---------------------|
| MDA (EVAR) [nmol/ml]       | 2.24               | 2.32            | 2.23*               |
| MDA (AFB) [nmol/ml]        | 2.07               | 2.2             | 1.88*               |
| P-value                    | > 0.05 (0.13)      | > 0.05 (0.27)   | < 0.05 (0.02)       |
| GSH (EVAR) [µmol/g Hb]     | 0.97*              | 1.72            | 1.02                |
| GSH (AFB) [µmol/g Hb]      | 2.56*              | 2.14            | 2.93                |
| P-value                    | < 0.05 (0.00)      | > 0.05 (0.14)   | > 0.05 (0.19)       |
| CAT (EVAR) [k/g Hb]        | 21.71              | 32.05           | 25.47               |
| CAT (AFB) [k/g Hb]         | 15.66              | 14.88           | 17.94               |
| P-value                    | > 0.05 (0.07)      | > 0.05 (0.06)   | > 0.05 (0.06)       |
| SOD (EVAR) [U/g Hb]        | 31.17*             | 35.53           | 31.15               |
| SOD (AFB) [U/g Hb]         | 29.18*             | 29.09           | 29.63               |
| P-value                    | < 0.05 (0.02)      | > 0.05 (0.07)   | > 0.05 (0.06)       |

*a,b Statistically significant groups.

| Parameter                  | Preoperative period | Operative period | Postoperative period |
|----------------------------|--------------------|-----------------|---------------------|
| MDA (EVAR) [nmol/ml]       | 2.24               | 2.32            | 2.23*               |
| MDA (AFB) [nmol/ml]        | 2.07               | 2.2             | 1.88*               |
| P-value                    | > 0.05 (0.13)      | > 0.05 (0.27)   | < 0.05 (0.02)       |
| GSH (EVAR) [µmol/g Hb]     | 0.97*              | 1.72            | 1.02                |
| GSH (AFB) [µmol/g Hb]      | 2.56*              | 2.14            | 2.93                |
| P-value                    | < 0.05 (0.00)      | > 0.05 (0.14)   | > 0.05 (0.19)       |
| CAT (EVAR) [k/g Hb]        | 21.71              | 32.05           | 25.47               |
| CAT (AFB) [k/g Hb]         | 15.66              | 14.88           | 17.94               |
| P-value                    | > 0.05 (0.07)      | > 0.05 (0.06)   | > 0.05 (0.06)       |
| SOD (EVAR) [U/g Hb]        | 31.17*             | 35.53           | 31.15               |
| SOD (AFB) [U/g Hb]         | 29.18*             | 29.09           | 29.63               |
| P-value                    | < 0.05 (0.02)      | > 0.05 (0.07)   | > 0.05 (0.06)       |

*a,b Statistically significant groups.
favour of the significant AOD group rather than the preoperative period. A matter that should be considered here is that open surgery was carried out in descending aortoiliac occlusive disease with continuous ischaemia and reperfusion attacks. High levels of preoperative GSH and low levels of postoperative MDA may be related to these chronic ischaemia and reperfusion attacks.

In the study by Lucas et al. in 2016, aorta specimens received from 10 cadaver organ donors in the control group were compared with the specimen taken from infrarenal aorta of nine severe aortoiliac stenosis (SAS) and seven total aortoiliac occlusion (TAO) patients during open surgery. Although the aortic ROS levels were higher in the TAO group than in the SAS group (48.3 ±10.22 vs. 33.02 ±4.54 pmol/mg protein), both were significantly higher than the control group. Likewise, when the SOD activities were examined, it was stated that although there was no difference in TAO and SAS groups, both were higher than the control group. Also, CAT activity was in parallel with the SOD activity. Of course, the fact that this study was built on local oxidant and anti-oxidant parameters and the cadaver control group were the most important factors to be criticised. Also, systemic oxidative status is highly valuable, but it can be affected by many systemic conditions like age and DM. However, the increase in the local antioxidant enzyme activity showed itself at various points in this study. When EVAR and AFB groups were evaluated both individually and jointly, no difference was observed apart from the fact that MDA, a lipid peroxidation product, was statistically significantly lower in the AFB group only in postoperative period. Even in this case, mean values were very close to each other. Although both these diseases and surgical practices cause an increase in oxidative stress, it can be seen that antioxidant activity can balance this.

In the study conducted by Papalambros et al., in 2007 regarding the MDA results obtained from 53 AAA patients undergoing open surgery, baseline MDA levels were found to be significantly higher than in the control group. A close correlation was observed between aortic clamping periods and MDA levels in blood samples taken at the 15th and 60th min after reperfusion following intensive care transfer, and elimination of this difference should be associated with the possible changes in the levels of antioxidant enzymes at the 24th h, but these values were not measured in this study. As in the present study, the constant elevation of MDA levels after 24 h might be due to the increasing GSH and CAT activity.

There is a mutation region regarding the conversion of valine amino acid (Val, GTT) on the 47th nucleotide in the 9th position of the MnSOD gene, as well as the alanine amino acid [9]. Also, generally in studies it is reported that patients possessing homozygous AA genotype in the diseases are associated with disease risk [9]. In this study, while there was no patient having an AA genotype, mutations with A allele were seen at the rate of 13%.

It was found that there was a genetic variation in which A in the 861<sup>th</sup> nucleotide of the GPx3 gene was converted into T, and this mutation was associated with the disease risks. In this study, T allele was seen at the rate of 83%.

In a previous study conducted on CAT gene, it was reported that T allele was significantly higher than the C allele; whereas, in the present study, no significance difference was observed between the alleles even though the C allele was present at the rate of 67% [10].

As a result, in the present study, the first findings regarding the antioxidant regions of patients included in a Turkish-origin sample group were obtained. The limitations of this study are the small patient groups and lack of comparison of the EVAR group with open surgery. Studies including further patients should be conducted to clearly determine which allele is associated with this disease.

In conclusion, in this single-centred pilot study, oxidative damage and some antioxidant parameters and genetic polymorphism of the antioxidant enzymes were discussed in endovascular repairs made for abdominal aortic aneurysms and aortofemoral by-passes in the aortoiliac lesions from daily routine procedures. From both perspectives, it is thought that the problems that may arise during these procedures, which are considered as very safe, are not related to oxidative damage.

Conflict of interest

The authors declare no conflict of interest.

References

1. Norgren L, Hiatt WR, Dormandy JA, Ehlers MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-67.
2. Lucas ML, Delbier L, Erlingir N, Lichtenfels E, Aerts N. Surgical treatment of chronic aortoiliac occlusion. J Vasc Bras 2015; 14: 29-36.
3. Lucas ML, Carraro CC, Bello-Klein A, Kalil AN, Aerts N. Oxidative stress in human aorta of patients with advanced aortoiliac occlusive disease. Braz J Cardiovasc Surg 2016; 31: 428-33.
4. Roy Chowdhury SK, Sangle GV, Xie X, Stelmacich GL, Halayko AJ, Shen GX. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells. Am J Physiol Endocrinol Metab 2010; 298: E89-E98.
5. Kuivanieniemi H, Ryer EJ, Elmore JR, Tramp G. Understanding the pathogenesis of abdominal aortic aneurysms. Expert Rev Cardiovasc Ther 2015; 13: 975-87.
6. Xiong W, Mactaggart J, Knispel R, et al. Inhibition of reactive oxygen species attenuates aneurysm formation in a murine model. Atherosclerosis 2009; 202: 128-34.
7. Piffaretti G, Mariscalco G, Riva F, Fontana F, Carrafiello G, Castelli P. Abdominal aortic aneurysm repair: long-term follow-up of endovascular versus open repair. Arch Med Sci 2014; 10: 273-82.
8. Breitling LP. Current genetics and epigenetics of smoking/tobacco-related cardiovascular disease. Arterioscler Thromb Vasc Biol 2013; 33: 1468-72.
9. Ambrosone CB, Freudenheim JL, Thompson PA, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 1999; 59: 602-6.
10. Forsberg L, Lyrenas L, Faire UD, Morgenstern R. A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic Biol Med 2001; 30: 500-5.
11. Goulas A, Fidani L, Kotsis A, et al. An association study of a functional catalase gene polymorphism, -262C-T, and patients with Alzheimer’s disease. Neurosci Lett 2002; 330: 210-2.
12. Cai Q, Shu XO, Wen W, et al. Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Breast Cancer Res 2004; 6: 647-55.
13. Voetsch B, Jin RC, Bierl C, et al. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: a novel risk factor for arterial ischemic stroke. Stroke 2007; 38: 41-9.
14. Mikolajczyk-Stecyna J, Korcz A, Gabriel M, Pawlaczyk K, Oszkinis G, Słomski R. Risk factors in abdominal aortic aneurysm and in Polish population aortoiliac occlusive disease and differences between them [corrected]. Sci Rep 2013; 3: 3528.
15. Placer ZA, Cushman L, Johnson BC. Estimation of products of lipid peroxidation (malondialdehyde) in biological fluids. Anal Biochem 1966; 16: 359-64.
16. Chavan S, Sava L, Saxena V, Pillais S, Sontakke A, Ingole D. Reduced glutathione: importance of specimen collection. Indian J Clin Biochem 2005; 20: 150-2.
17. Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121-6.
18. Sun Y, Oberley WL, Li YA. Simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 97-500.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor Laboratory Press 1989.
20. Lucas ML, Carraro CC, Belló-Klein A, Kalil AN, Aerts N. Oxidative stress in human aorta of patients with advanced aortoiliac occlusive disease. Braz J Cardiovasc Surg 2016; 31: 428-33.
21. Trocha M, Merwid-Lad A, Pieśniewska M, et al. Age-related differences in function and structure of rat livers subjected to ischemia/reperfusion. Arch Med Sci 2018; 14: 388-95.